Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice

Archives of Physiology and Biochemistry

Volumn 113, Issue 4-5, 2007, Pages 211-220

  How, O J ^a   Larsen, T S ^a   Hafstad, A D ^a   Khalid, A ^a   Myhre, E S P ^a   Murray, A J ^b,c   Boardman, N T ^a   Cole, M ^b   Clarke, K ^b   Severson, D L ^d   Aasum, E ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cardiac efficiency; Diabetes mellitus; Energy metabolism; Fatty acids; Myocardial oxygen consumption; Pressure volume analysis; Uncoupling proteins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ION CHANNEL; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN 3; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BODY WEIGHT; C57BL MOUSE; CARDIOVASCULAR FUNCTION; CORONARY BLOOD VESSEL; DRUG EFFECT; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; HEART; HEART VENTRICLE FUNCTION; ISCHEMIA; LIPID METABOLISM; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN SIZE; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR PHYSIOLOGY; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; FEMALE; HEART; ION CHANNELS; ISCHEMIA; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; ORGAN SIZE; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; REPERFUSION INJURY; RNA, MESSENGER; THIAZOLIDINEDIONES; VENTRICULAR FUNCTION;

MUS;

EID: 37548999000     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450701783281     Document Type: Article

References (48)

1. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, Larsen TS. 2002. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 283:H949-H957.
2. Aasum E, Hafstad AD, Severson DL, Larsen TS. 2003. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52:434-41.
3. Allard MF. 2004. Energy substrate metabolism in cardiac hypertrophy. Curr Hypertens Rep 6:430-5.
4. An D, Rodrigues B. 2006. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291:H1489-506.
5. Aronson D, Rayfield EJ, Chesebro JH. 1997. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 126:296-306.
6. Belke DD, Swanson EA, Dillmann WH. 2004. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53:3201-8.
7. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. 2001. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am J Physiol Heart Circ Physiol 280:H977-83.
8. Boss O, Hagen T, Lowell BB. 2000. Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes 49:143-56.
9. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, Abel ED. 2005. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112:2686-95.
10. Burkhoff D, Weiss RG, Schulman SP, Kalil-Filho R, Wannenburg T, Gerstenblith G. 1991. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol 261:H741-50.
11. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. 2005. Biochim Biophys Acta 1734:112-26.
12. Carley AN, Atkinson LL, Bonen A, Harper ME, Kunnathu S, Lopaschuk GD, Severson DL. 2007. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch.Physiol.Biochem. 113(2):65-75.
13. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. 2003. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328-35.
14. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. 2003. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100:1226-31.
15. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. 2006. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 119:591-9.
16. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-105.
17. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, Van der Vusse GJ, Staels B, van Bilsen M. 2003. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518-24.
18. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ. 2005. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-54.
19. Graham TPJ, Covell JW, Sonnenblick EH, Ross JJ, Braunwald E. 1968. Control of myocardial oxygen consumption: relative influence of contractile state and tension development. J Clin Invest 47:375-85.
20. Grossman W, Jones D, McLaurin LP. 1975. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56-64.
21. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E. 2007. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab 292:E1288-94.
22. How OJ, Aasum E, Kunnathu S, Severson DL, Myhre ES, Larsen TS. 2005. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol 288:H2979-85.
23. How OJ, Aasum E, Severson DL, Chan A, Essop F, Larsen TS. 2006. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55:466-473.
24. Jones SP, Girod WG, Granger DN, Palazzo AJ, Lefer DJ. 1999. Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am J Physiol 277:H763-69.
25. Kim SH, Abbasi F, Chu JW, McLaughlin TL, Lamendola C, Polonsky KS, Reaven GM. 2005. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 54:2447-52.
26. Korvald C, Elvenes OP, Myrmel T. 2000. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 278:H1345-51.
27. Korvald C, Elvenes OP, Aghajani E, Myhre ES, Myrmel T. 2001. Postischemic mechanoenergetic inefficiency is related to contractile dysfunction and not altered metabolism. Am J Physiol Heart Circ Physiol 281:H2645-53.
28. Mjos OD. 1971. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 50:1386-9.
29. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. 2004. Uncoupling proteins in human heart. Lancet 364: 1786-8.
30. Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K. 2005. Plasma free fatty acids and peroxisome proliferator-activated receptor {alpha} in the control of myocardial uncoupling protein levels. Diabetes 54:3496-502.
31. Myrmel T, Forsdahl K, Larsen TS. 1992. Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol 24:855-68.
32. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. 2003. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. 7 October 2003. Circulation 108:2941-8.
33. Ohgoshi Y, Goto Y, Kawaguchi O, Yaku H, Takaoka H, Hata K, Takasago T, Suga H. 1992. Epinephrine and calcium have similar oxygen costs of contractility. Heart Vessels 7:123-32.
34. Opie LH. 2004. Heart Physiology from Cell to Circulation. Philadelphia, PA: Lippincott Williams and Wilkins; pp 279-431.
35. Peterson LR, Waggoner AD, Herrero P, Racette S, Meyer T, las-Fuentes L, Klein S, Davila-Roman VG, Gropler RJ. 2003. Glucose intolerance and obesity alter myocardial metabolism in young women. J Am Coll Cardiol 41:428.
36. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. 2004. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109:2191-6.
37. Picard F, Auwerx J. 2002. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167-97.
38. Pilz S, Scharnagl H, Tiran B, Seelhorst U, Wellnitz B, Boehm BO, Schaefer JR, Marz W. 2006. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab 91:2542-7.
39. Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806.
40. Schernthaner G. 1996. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 31:S3-13.
41. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. 2003. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107:3040-6.
42. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K 2002. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51:1110-7.
43. Singh S, Loke YK, Furberg CD. 2007. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-95.
44. Suga H. 1979. Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J Physiol 236:H498-505.
45. Suga H. 1990. Ventricular energetics. Physiol Rev 70:247-77.
46. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA. 1999. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 67:1045-52.
47. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. 2005. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 54:554-62.
48. Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, Buckingham R, Williams G. 1997. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 122: 1405-10.